, Tracking Stock Market Picks
Enter Symbol:
Intermune, Inc. (ITMN) [hlAlert]

up 447.81 %

Intermune, Inc. (ITMN) rated Outperform with price target $50 by Wedbush Morgan

Posted on: Wednesday,  Mar 10, 2010  9:25 AM ET by Wedbush Morgan

Wedbush Morgan rated Outperform Intermune, Inc. (NASDAQ: ITMN) on 03/10/2010. Previously Wedbush Morgan rated Outperform Intermune, Inc. (NASDAQ: ITMN) on 10/21/2009.,
when the stock price was $13.49. Since then, Intermune, Inc. has gained 447.81% as of 09/26/2014's recent price of $73.90.
If you would have followed the previous Wedbush Morgan's recommendation on ITMN, you would have gained 447.81% of your investment in 1801 days.

InterMune Pharmaceuticals Inc. develops and commercializes innovative products for the treatment of serious pulmonary and infectious diseases and congenital disorders. The company markets ACTIMMUNE for chronic granulomatous disease and osteopetrosis. The company has active development programs underway for the other disease areas, several of which are in mid-or advanced-stage human testing, known as clinical trials.

Since 1980, WEDBUSH has used its private equity discipline to invest in under-valued and capital constrained public and private companies that have a significant potential for appreciation. The firm invests with high quality management teams with domain expertise and expects management to retain or make a personally significant equity investment.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/10/2010 9:25 AM Buy
38.34 50.00
as of 12/31/2010
1 Week down  -5.29 %
1 Month up  179.37 %
3 Months up  157.63 %
1 YTD up  169.09 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/21/2009 9:25 AM Buy
13.49 23.00
8/7/2009 9:25 AM Hold
14.57 19.00
3/18/2009 9:25 AM Hold

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy